AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Shares ...

AbbVie's shares dropped off a cliff in November after it announced a clinical setback for emraclidine, an investigational ...

The S&P 500 edged 0.2% higher on Tuesday, March 25, despite a report showing that consumer confidence fell to its lowest ...

Genmab denies the accusation that it knowingly stole confidential information in a $1.8 billion deal to acquire a cancer drug ...

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the ...

As AbbVie accuses Genmab of unlawfully using proprietary ADC technology, find out about their collaboration and the dispute ...

We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look ...

Company Announcement AbbVie Inc. files complaint against Genmab in the U.S. District Court for the Western District of Washington (Seattle)Genmab categorically refutes allegations and will vigorously ...

OBT has entered a multi-year partnership with Roche to discover antibody-based therapeutics for cancer treatment.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

These four companies have raised their dividends over an impressive streak of 25 years or more. The post 4 US Dividend ...

Taiho Pharmaceutical has agreed to acquire Swiss-based antibody-drug-conjugate (ADC) specialist Araris Biotech for up to ...